Comparison between Corona Remedies IPO and Urban Company IPO.
Corona Remedies IPO is a Mainboard Bookbuilding IPO proposed to list at BSE, NSE while Urban Company IPO is a Mainboard Bookbuilding proposed to list at BSE, NSE.
The total issue size of Corona Remedies IPO is up to ₹655.37 Cr whereas the issue size of the Urban Company IPO is up to ₹1,900.24 Cr. The final issue price of Corona Remedies IPO is ₹1,062.00 per share and of Urban Company IPO is ₹103.00 per share.
| Corona Remedies IPO | Urban Company IPO | |
|---|---|---|
| Face Value | ₹10 per share | ₹1 per share |
| Issue Price (Lower) | ₹1,008.00 per share | ₹98.00 per share |
| Issue Price (Upper) | ₹1,062.00 per share | ₹103.00 per share |
| Issue Price (Final) | ₹1,062.00 per share | ₹103.00 per share |
| Discount (Retail) | ||
| Discount (Employee) | ₹54.00 per share | ₹9.00 per share |
| Market Lot Size | 14 shares | 145 shares |
| Fresh Issue Size | 0 shares | 4,58,48,481 shares |
| Fresh Issue Size (Amount) | up to ₹0.00 Cr | up to ₹472.24 Cr |
| OFS Issue Size | 61,74,051 shares | 13,86,40,774 shares |
| OFS Issue Size (Amount) | up to ₹655.37 Cr | up to ₹1,428.00 Cr |
| Issue Size Total | 61,74,051 shares | 18,44,89,255 shares |
| Issue Size Total (Amount) | up to ₹655.37 Cr | up to ₹1,900.24 Cr |
Corona Remedies IPO opens on Dec 08, 2025, while Urban Company IPO opens on Sep 10, 2025. The closing date of Corona Remedies IPO and Urban Company IPO is Dec 10, 2025, and Sep 12, 2025, respectively.
| Corona Remedies IPO | Urban Company IPO | |
|---|---|---|
| Anchor Bid Date | Dec 05, 2025 | Sep 09, 2025 |
| Issue Open | Dec 08, 2025 | Sep 10, 2025 |
| Issue Close | Dec 10, 2025 | Sep 12, 2025 |
| Basis Of Allotment (Tentative) | Dec 11, 2025 | Sep 15, 2025 |
| Initiation of Refunds (Tentative) | Dec 12, 2025 | Sep 16, 2025 |
| Credit of Share (Tentative) | Dec 12, 2025 | Sep 16, 2025 |
| Listing date (Tentative) | Dec 15, 2025 | Sep 17, 2025 |
| Anchor Lockin End date 1 | Jan 09, 2026 | Oct 16, 2025 |
| Anchor Lockin End date 2 | Mar 10, 2026 | Dec 14, 2025 |
Corona Remedies IPO P/E ratio is 43.47, as compared to Urban Company IPO P/E ratio of 59.71.
| Corona Remedies IPO | Urban Company IPO | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financials | Company Financials (Restated Consolidated)Corona Remedies Ltd.'s revenue increased by 18% and profit after tax (PAT) rose by 65% between the financial year ending with March 31, 2025 and March 31, 2024.
| Company Financials (Restated Consolidated)Urban Co.Ltd.'s revenue increased by 36% and profit after tax (PAT) rose by 358% between the financial year ending with March 31, 2025 and March 31, 2024.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 72.5 | 59.88 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | 69 | 20.43 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| P/E Ratio | 43.47 | 59.71 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Market Cap | ₹6495.20 Cr. | ₹14789.55 Cr. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROE | 27.50% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROCE | 41.32% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt/Equity | 0.10 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EPS | ₹24.43 | ₹1.72 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RoNW | 24.65% | 13.35% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In the Corona Remedies IPO Retail Individual Investors (RII) are offered 21,40,606 shares while in Urban Company IPO retail investors are offered 21,40,606 shares. Qualified Institutional Buyers (QIB) are offered 12,23,203 shares in Corona Remedies IPO and 5,52,66,990 shares in Urban Company IPO.
| Corona Remedies IPO | Urban Company IPO | |
|---|---|---|
| Anchor Investor Reservation | 18,34,804 shares | 8,29,00,485 shares |
| Market Maker Reservation | 0 shares | 0 shares |
| QIB | 12,23,203 shares | 5,52,66,990 shares |
| NII | 9,17,403 shares | 2,76,33,494 shares |
| RII | 21,40,606 shares | 1,84,22,329 shares |
| Employee | 58,035 shares | 2,65,957 shares |
| Others | ||
| Total | 61,74,051 shares | 18,44,89,255 shares |
Corona Remedies IPO subscribed 144.54x in total, whereas Urban Company IPO subscribed 108.98x.
| Corona Remedies IPO | Urban Company IPO | |
|---|---|---|
| QIB (times) | 293.80x | 147.35x |
| NII (times) | 220.18x | 77.82x |
| Big NII (times) | 246.67x | 86.75x |
| Small NII (times) | 167.20x | 59.95x |
| RII (times) | 30.39x | 41.49x |
| Employee (times) | 15.56x | 42.55x |
| Other (times) | ||
| Total (times) | 144.54x | 108.98x |
